KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Amgen (AMGN) EBIAT (2016 - 2025)

Amgen has reported EBIAT over the past 17 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put EBIAT at $1.3 billion for Q4 2025, up 112.6% from a year ago — trailing twelve months through Dec 2025 was $7.7 billion (up 88.53% YoY), and the annual figure for FY2025 was $7.7 billion, up 88.53%.
  • EBIAT for Q4 2025 was $1.3 billion at Amgen, down from $3.2 billion in the prior quarter.
  • Over the last five years, EBIAT for AMGN hit a ceiling of $3.2 billion in Q3 2025 and a floor of -$113.0 million in Q1 2024.
  • Median EBIAT over the past 5 years was $1.5 billion (2022), compared with a mean of $1.5 billion.
  • Biggest five-year swings in EBIAT: crashed 103.98% in 2024 and later skyrocketed 1630.97% in 2025.
  • Amgen's EBIAT stood at $1.9 billion in 2021, then fell by 14.9% to $1.6 billion in 2022, then crashed by 52.54% to $767.0 million in 2023, then decreased by 18.25% to $627.0 million in 2024, then skyrocketed by 112.6% to $1.3 billion in 2025.
  • The last three reported values for EBIAT were $1.3 billion (Q4 2025), $3.2 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.